RecruitingPhase II🇵🇱 PolandEN originalLeukemia

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Zdiagnozowana przewlekła białaczka limfocytowa (lub chłoniak limfocytowy z małych komórek) zgodnie z najnowszymi kryteriami diagnostycznymi.
  • Dobra ogólna kondycja fizyczna pozwalająca na uczestnictwo w badaniu (oceniana w skali ECOG).
  • Widoczne powiększenie węzłów chłonnych w badaniu obrazowym (np. tomografii komputerowej).

✗ Disqualifies

  • Niekontrolowana niedokrwistość autoimmunohemolityczna lub małopłytkowość autoimmunohemolityczna, wymagająca leczenia sterydami.
  • Znane zaburzenia krzepnięcia krwi.
  • Udar mózgu lub krwawienie do mózgu w ciągu ostatnich 6 miesięcy.
  • Podejrzenie lub potwierdzona transformacja Richtera (przekształcenie białaczki w inny typ chłoniaka) lub zajęcie ośrodkowego układu nerwowego.
  • Ciężkie, aktywne choroby serca, takie jak niekontrolowane zaburzenia rytmu serca lub zaawansowana niewydolność serca.

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 6, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (74)

The Oncology Institute Clinical Research

Cerritos, United States

Cancer and Blood Specialty Clinic

Los Alamitos, United States

SLO Oncology and Hematology Health Center

San Luis Obispo, United States

Providence Medical Foundation

Santa Rosa, United States

PIH Health Hospital

Whittier, United States

Grand Valley Oncology

Grand Junction, United States

Mount Sinai Medical Center Campus

Miami Beach, United States

The Oncology Institute

North Miami Beach, United States

Mid Florida Hematology Oncology

Orange, United States

Boise VA Medical Center

Boise, United States

Hope and Healing Cancer Services

Hinsdale, United States

Springfield Clinic

Springfield, United States

Iowa City VA Health Care System

Iowa City, United States

Minnesota Oncology Hematology P A

Minneapolis, United States

Research Medical Center

Kansas City, United States

Hunterdon Hematology Oncology

Flemington, United States

Summit Medical Group

Florham Park, United States

Hematology Oncology Associates of Rockland

Nyack, United States

Southeastern Medical Oncology Center

Goldsboro, United States

Oncology Hematology Care

Cincinnati, United States

Willamette Valley Cancer Institute and Research Center

Eugene, United States

OHSU Knight Cancer Institute

Portland, United States

Renovatio Clinical

El Paso, United States

Texas Oncology-Fort Worth Cancer Center

Fort Worth, United States

The University of Texas MD Anderson Cancer Center

Houston, United States

Renovatio Clinical 1

The Woodlands, United States

Texas Oncology-Gulf Coast

The Woodlands, United States

Community Cancer Trials of Utah

Ogden, United States

Virginia Cancer Specialists

Manassas, United States

Virginia Oncology Associates

Virginia Beach, United States

VA Puget Sound Healthcare System

Seattle, United States

Northwest Cancer Specialists PC

Vancouver, United States

QEII Health Sciences Centre

Halifax, Canada

Niagara Health System

St. Catharines, Canada

Fakultni nemocnice Brno

Brno-Bohunice, Czechia

Fakultni nemocnice Hradec Kralove

Hradec Králové, Czechia

Fakultni nemocnice Olomouc

Olomouc, Czechia

Fakultni Nemocnice Ostrava

Ostrava - Poruba, Czechia

Fakultni nemocnice Kralovske Vinohrady

Prague, Czechia

Ustav Hematologie A Krevni Transfuze

Prague, Czechia

CHU de Clermont Ferrand

Clermont-Ferrand, France

CHU Nantes

Nantes, France

Hopital Pitie Salpetriere

Paris, France

CHU Lyon Sud

Pierre-Bénite, France

CHU de Reims

Reims, France

Institut de Cancerologie Strasbourg Europe ICANS

Strasbourg, France

Semmelweis Egyetem

Budapest, Hungary

Gyor Moson Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz

Győr, Hungary

Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz

Nyíregyháza, Hungary

University of Szeged

Szeged, Hungary

U.O. Ematologia Istituto Tumori Giovanni Paolo II

Bari, Italy

Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant Anna

Ferrara, Italy

Azienda Ospedaliero Universitaria Careggi

Florence, Italy

Ospedale San Raffaele

Milan, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

Ospedale Maggiore della Carita

Novara, Italy

Universita degli Studi di Padova Azienda Ospedaliera di Pa

Padova, Italy

Ospedale Villa Sofia-Cervello

Palermo, Italy

Azienda Ospedaliera di Perugia Ospedale S.Maria della Misericordia

Perugia, Italy

Ematologia Fondazione Univ. Policlinico Gemelli Università Cattolica del Sacro Cuore

Roma, Italy

Umberto I Policlinico di Roma

Roma, Italy

Wojewodzki Szpital Specjalistyczny

Biała Podlaska, Poland

Szpital Specjalistyczny w Brzozowie

Brzozów, Poland

Szpitale Pomorskie Sp z o o

Gdynia, Poland

Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach

Kielce, Poland

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

Krakow, Poland

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi

Lodz, Poland

Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli

Lublin, Poland

Hosp Univ Vall D Hebron

Barcelona, Spain

Hosp Reina Sofia

Córdoba, Spain

Hosp. Univ. Ramon Y Cajal

Madrid, Spain

Hosp. Univ. 12 de Octubre

Madrid, Spain

Hosp. Univ. Marques de Valdecilla

Santander, Spain

Hosp. Clinico Univ. de Santiago

Santiago de Compostela, Spain

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.